Asthma Management in Adolescents

Treatment Guidelines

The American Academy of Allergy, Asthma, and Immunology recommends high-dose ICS/LABA combination as the foundation therapy for a 13-year-old with severe/advanced asthma 3, 2
The National Asthma Education and Prevention Program guidelines suggest adding omalizumab if the patient has allergic asthma with documented IgE-mediated sensitization to perennial aeroallergens 1, 4
The American College of Allergy, Asthma, and Immunology recommends adding oral systemic corticosteroids only if control remains inadequate despite high-dose ICS/LABA plus omalizumab 3, 2

The FDA warns that LABAs must never be used as monotherapy due to increased severe exacerbations and deaths when used alone 3, 5
The American Academy of Allergy, Asthma, and Immunology advises that LABAs should only be prescribed in fixed-dose combination with ICS 1, 3
The National Asthma Education and Prevention Program guidelines state that omalizumab is indicated for patients ≥12 years old with documented allergic asthma and positive skin testing or RAST to perennial allergens 1, 4

The American Academy of Allergy, Asthma, and Immunology recommends verifying adherence to current medications, proper inhaler technique, environmental control measures, and addressing comorbid conditions before escalating therapy 3, 2
The National Asthma Education and Prevention Program guidelines suggest that using SABA >2 days/week for symptom relief indicates inadequate control requiring treatment intensification 3, 2